journal article·2018-10-31Open access

Formulation of sitagliptin-loaded oral polymeric nano scaffold: process parameters evaluation and enhanced anti-diabetic performance

Mohammed Asadullah Jahangir, Ruqaiyah Khan, Syed Sarim Imam

Abstract

PURPOSE: The aim of the study to formulate and statistically optimize sitagliptin-loaded eudragit nanoparticles (SIT-NPs) and evaluate the in-vitro pharmaceutical quality and in-vivo anti-diabetic assessment. METHOD: SIT-NPs were prepared by using combination method of solvent evaporation and nano-precipitation techniques. The influence of different independent variables as eudragit RL100 concentration (%), tween 80 concentration (%) and sonication time (min) were evaluated on dependent variables like particle size (nm), drug loading (%) and in-vitro drug release (%). Further, the optimized formulation was evaluated for surface morphology, CLSM, ex-vivo permeation study and in-vivo anti-diabetic activity and stability study. RESULTS: The developed SIT-NPs formulations showed particle size range (135.86-193.45 nm), drug loading (6.36-8.76%) and prolonged drug release over 24 h. The prepared SIT-NPs were found to be nearly spherical with smooth surface. The comparative in-vitro release study and CLSM study results revealed that SIT-NPopt showed significantly (p < .05) enhanced release and permeation as compared to SIT free solution (SIT-Fs). The in-vivo anti-diabetic assessment revealed that SIT-NPopt able to reduce the blood sugar level (BSL) for a prolonged period of time. Further, the stability study data showed the formulations were found stable at both temperature and having the shelf life of 488 d. CONCLUSIONS: This research has shown that SIT-NPs based on experimental design offers a new and better approach to delivering SIT, thus encouraging further development of this formulation.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Advanced Drug Delivery Systems · Drug Solubulity and Delivery Systems · Advancements in Transdermal Drug Delivery

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Pharmaceutics, School of Pharmacy, Glocal University

Department of Pharmacology, Siddhartha Institute of Pharmacy

References (41)

Show source-provided references
1. Jahangir MA, Imam SS, Kazmi I, et al. Type 2 diabetes current and future medications: a short review. Int J Pharm Pharmacol. 2017;1:101.
2. 10.1177/009127000628985010.1177/0091270006289850 ↗
3. 10.3109/02652048.2012.72072210.3109/02652048.2012.720722 ↗
4. Prasanthi S, Prasad AR, Kumar YG, et al. Formulation and evaluation of sitagliptin phosphate and simvastatin bilayered tablets. Indo Am J Pharm Res. 2015;5:2231–6876.
5. Maringanti PS, Nalagonda C. Formulation and evaluation of sitagliptin phosphate and metformin hydrochloride trilayered tablets. Int J Drug Deliv. 2013;5:15.
6. Keerthi K, Kothamasu A, Makineni SN, et al. Formulation and evaluation of sitagliptin phosphate gastro retentive tablets. Carib J Sci Tech. 2014;2:270–281.
7. 10.3109/21691401.2014.90982010.3109/21691401.2014.909820 ↗
8. 10.3109/10837450.2011.60478310.3109/10837450.2011.604783 ↗
9. 10.3109/21691401.2014.96530910.3109/21691401.2014.965309 ↗
10. 10.1080/21691401.2017.133702710.1080/21691401.2017.1337027 ↗
11. 10.1016/j.biopha.2016.03.04210.1016/j.biopha.2016.03.042 ↗
12. 10.1016/j.colsurfb.2009.08.05010.1016/j.colsurfb.2009.08.050 ↗
13. 10.3109/10837450.2015.110898310.3109/10837450.2015.1108983 ↗
14. Wadher KJ, Nagarkar A, Sahare D, et al. Formulation and evaluation of sustained release ciprofloxacin hydrocloride microspheres using synthetic polymers. Int J Pharm Tech Res. 2013;5:773–780.
15. 10.3109/10837450.2015.104104410.3109/10837450.2015.1041044 ↗
16. 10.1208/s12249-012-9833-010.1208/s12249-012-9833-0 ↗
17. 10.1016/j.ijbiomac.2014.04.01910.1016/j.ijbiomac.2014.04.019 ↗
18. 10.1016/j.ijpharm.2012.06.05410.1016/j.ijpharm.2012.06.054 ↗
19. 10.1016/j.jsps.2012.02.00110.1016/j.jsps.2012.02.001 ↗
20. 10.1615/CritRevTherDrugCarrierSyst.v22.i1.2010.1615/CritRevTherDrugCarrierSyst.v22.i1.20 ↗
21. 10.1016/j.intimp.2015.10.02910.1016/j.intimp.2015.10.029 ↗
22. 10.1016/j.biopha.2017.06.04310.1016/j.biopha.2017.06.043 ↗
23. 10.3109/21691401.2016.113848610.3109/21691401.2016.1138486 ↗
24. 10.3109/10717544.2014.93653610.3109/10717544.2014.936536 ↗
25. 10.3109/10717544.2014.92395810.3109/10717544.2014.923958 ↗
26. 10.1021/acs.molpharmaceut.6b0058610.1021/acs.molpharmaceut.6b00586 ↗
27. 10.3109/21691401.2015.110274210.3109/21691401.2015.1102742 ↗
28. 10.3109/10717544.2013.87026010.3109/10717544.2013.870260 ↗
29. 10.1016/j.nano.2005.12.00310.1016/j.nano.2005.12.003 ↗
30. 10.1016/j.msec.2017.02.14910.1016/j.msec.2017.02.149 ↗
31. 10.1016/j.ultsonch.2017.09.04210.1016/j.ultsonch.2017.09.042 ↗
32. 10.1016/j.ijpharm.2010.04.03910.1016/j.ijpharm.2010.04.039 ↗
33. 10.1016/S0928-0987(01)00095-110.1016/S0928-0987(01)00095-1 ↗
34. 10.2174/156720181366616123014171710.2174/1567201813666161230141717 ↗
35. 10.5740/jaoacint.11-38310.5740/jaoacint.11-383 ↗
36. Arora S, Ojha SK, Vohora D. Characterisation of Streptozotocin induced diabetes mellitus in Swiss albino mice. Glob J Pharm. 2009;3:81–84.
37. 10.3109/21691401.2016.116769910.3109/21691401.2016.1167699 ↗
38. Mallamma T, Bharathi DR, Lakshmi RG, et al. Etoposide-loaded nanoparticles made from poly-e-caprolactone (PCL): formulation characterization, in vitro drug release for controlled drug delivery system. Int J Biopharm. 2014;5:5–12.
39. Abdallah MH. Box-behnken design for development and optimization of acetazolamide microspheres. Int J Pharm Sci Res. 2014;5:1228–1239.
40. 10.2174/1567201811310999004110.2174/15672018113109990041 ↗
41. 10.1517/17425247.2014.87600410.1517/17425247.2014.876004 ↗